SUMMIT THERAPEUTICS INC.
601 Brickell Key Drive, Suite 1000
Miami, FL 33131
(650) 460-8308
February 23, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Summit Therapeutics Inc. |
| Registration Statement on Form S-3 | |
| File No. 333-277169 | |
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Summit Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-277169) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on February 27, 2024 or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
| (a) | should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; |
| (b) | the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and |
| (c) | the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We request that we be notified of such effectiveness by a telephone call to Adam Finerman, of Baker & Hostetler LLP, at (212) 589-4233 or afinerman@bakerlaw.com.
[Remainder of this page is intentionally left blank] |
| Very truly yours, | ||
| SUMMIT THERAPEUTICS INC. | ||
| By: | /s/ Ankur Dhingra | |
| Name: | Ankur Dhingra | |
| Title: | Chief Financial Officer | |